A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is compare the relative bioavailability of 750 mg Metformin
Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg
GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750
mg) in healthy adult volunteers under non-fasting conditions